Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
Baas DJH, Schilham M, Hermsen R, de Baaij JMS, Vrijhof HJEJ, Hoekstra RJ, Sedelaar JPM, Küsters-Vandevelde HVN, Gotthardt M, Wijers CHW, van Basten JP, Somford DM. Baas DJH, et al. Prostate Cancer Prostatic Dis. 2022 Mar;25(1):65-70. doi: 10.1038/s41391-021-00452-y. Epub 2021 Sep 1. Prostate Cancer Prostatic Dis. 2022. PMID: 34471231
Lymph node staging with fluorine-18 prostate specific membrane antigen 1007-positron emission tomography/computed tomography in newly diagnosed intermediate- to high-risk prostate cancer using histopathological evaluation of extended pelvic node dissection as reference.
Hermsen R, Wedick EBC, Vinken MJM, van Kalmthout LWM, Küsters-Vandevelde HVN, Wijers CHW, Somford DM, van Basten JA. Hermsen R, et al. Eur J Nucl Med Mol Imaging. 2022 Sep;49(11):3929-3937. doi: 10.1007/s00259-022-05827-4. Epub 2022 May 11. Eur J Nucl Med Mol Imaging. 2022. PMID: 35543733 Clinical Trial.
Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome.
van Wilpe S, Sultan S, Gorris MAJ, Somford DM, Kusters-Vandevelde HVN, Koornstra RHT, Gerritsen WR, Simons M, van der Heijden AG, de Vries IJM, Mehra N. van Wilpe S, et al. Cancer Immunol Immunother. 2023 Jan;72(1):137-149. doi: 10.1007/s00262-022-03234-0. Epub 2022 Jun 30. Cancer Immunol Immunother. 2023. PMID: 35771253 Free PMC article.
Reply to Francesco Montorsi, Simone Scuderi, Alberto Briganti, and Giorgio Gandaglia's Letter to the Editor re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with Newly Diagnosed Prostate Cancer in the Years to Come. Eur Urol 2022;82:578-80.
Schilham MGM, Rijpkema M, Scheenen T, Hermsen R, Barentsz JO, Sedelaar JPM, Kusters-Vandevelde H, Kerkmeijer LGW, Somford DM, Gotthardt M. Schilham MGM, et al. Among authors: kusters vandevelde h. Eur Urol. 2023 May;83(5):e133-e134. doi: 10.1016/j.eururo.2023.01.023. Epub 2023 Feb 11. Eur Urol. 2023. PMID: 36781337 No abstract available.
Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer.
Exterkate L, Hermsen R, Küsters-Vandevelde HVN, Prette JF, Baas DJH, Somford DM, van Basten JA. Exterkate L, et al. Among authors: kusters vandevelde hvn. Eur Urol Oncol. 2023 Dec;6(6):574-581. doi: 10.1016/j.euo.2023.04.006. Epub 2023 May 23. Eur Urol Oncol. 2023. PMID: 37230883
51 results